CANY
CLB icon

Caxton Associates (New York)’s Core Laboratories CLB Stock Holding History

Caxton Associates (New York)’s Portfolio CLB Stock Details CLB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-19,397
Closed -$201K – 480
2020
Q1 		$201K Buy
+19,397
New +$542K 0.04% 354

Other funds holding CLB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

Caxton Associates (New York)'s CLB Position: Q2 2020 in Review

Caxton Associates (New York) sold out of Core Laboratories (CLB) in Q2 2020, closing a stake of 19,397 shares — an estimated $201K sold.

Caxton Associates (New York) first reported a position in CLB in Q1 2020 and held it in 1 quarter. The position peaked at $201K in Q1 2020. 197 funds tracked by Wall St. Rank hold CLB as of Q2 2020.

  • Caxton Associates (New York) reported no remaining Core Laboratories position as of Q2 2020 after selling out during the quarter.
  • Caxton Associates (New York) sold 19,397 Core Laboratories shares in Q2 2020, an estimated $201K.
  • Caxton Associates (New York) first reported a position in Core Laboratories in Q1 2020 and held it in 1 quarter.
  • Caxton Associates (New York)'s Core Laboratories position peaked at $201K in Q1 2020.
  • 197 funds tracked by Wall St. Rank held Core Laboratories as of Q2 2020.

Based on Caxton Associates (New York)'s 13F filing for Q2 2020, filed 14 Aug 2020.